Industrialization of Drug Discovery
From Target Selection Through Lead Optimization
Seiten
2021
CRC Press (Verlag)
978-1-032-09994-1 (ISBN)
CRC Press (Verlag)
978-1-032-09994-1 (ISBN)
The pharmaceutical industry suffers from an innovation deficit, with clinical attrition and safety-related market-withdrawal rates at the same level as twenty years ago. This book scrutinizes this problem in detail, contrasting the promise of technology and industrialization with the apparent inability of industry to fully realize the tools that ar
The drug discovery and development process is getting longer, more expensive, and no better. The industry suffers from the same clinical attrition and safety-related market withdrawal rates today as it did 20 years ago. Industrialization of Drug Discovery: From Target Selection Through Lead Optimization scrutinizes these problems in detail, contrasting the promise of technology and industrialization with the challenges of using the tools available to their best advantage. The book explores early successes, examines the current state of the art, and provides a strategic analysis of the issues currently facing drug discovery.
Introducing the historical background and current status of the industry, the book delineates the basic tenets underlying modern drug discovery, how they have evolved, and their use in various approaches and strategies. It examines, in detail, the regulations, requirements, guidelines, and draft documents that guide so many FDA actions. The editor devotes the remainder of the discussion to industrialization, compound and knowledge management functions, the drug screening process, collaboration, and finally, ethical issues.
Drawing on real-life, from-the-trenches examples, the book elucidates a new approach to drug discovery and development. This modern-day, back-to-basics approach includes three steps: understand the science, unravel the story, and then intelligently apply the technology, bringing to bear the entire armamentarium of industrialization techniques, not just automation, to the discovery process. Using these steps, you can meet the goals of more specific targets, more selective compounds, and decreased cycle times. In effect, you can look for a bigger needle in a smaller haystack.
Daniel E. Levy, editor of the Drug Discovery Series, is the founder of DEL BioPharma, a consulting service for drug discovery programs. He also maintains a blog that explores organic chemistry.
The drug discovery and development process is getting longer, more expensive, and no better. The industry suffers from the same clinical attrition and safety-related market withdrawal rates today as it did 20 years ago. Industrialization of Drug Discovery: From Target Selection Through Lead Optimization scrutinizes these problems in detail, contrasting the promise of technology and industrialization with the challenges of using the tools available to their best advantage. The book explores early successes, examines the current state of the art, and provides a strategic analysis of the issues currently facing drug discovery.
Introducing the historical background and current status of the industry, the book delineates the basic tenets underlying modern drug discovery, how they have evolved, and their use in various approaches and strategies. It examines, in detail, the regulations, requirements, guidelines, and draft documents that guide so many FDA actions. The editor devotes the remainder of the discussion to industrialization, compound and knowledge management functions, the drug screening process, collaboration, and finally, ethical issues.
Drawing on real-life, from-the-trenches examples, the book elucidates a new approach to drug discovery and development. This modern-day, back-to-basics approach includes three steps: understand the science, unravel the story, and then intelligently apply the technology, bringing to bear the entire armamentarium of industrialization techniques, not just automation, to the discovery process. Using these steps, you can meet the goals of more specific targets, more selective compounds, and decreased cycle times. In effect, you can look for a bigger needle in a smaller haystack.
Daniel E. Levy, editor of the Drug Discovery Series, is the founder of DEL BioPharma, a consulting service for drug discovery programs. He also maintains a blog that explores organic chemistry.
Jeffrey S. Handen, Ph.D.
Drug Discovery in the Modern Age: How We Got Here and Where Do We Go?. The Regulatory Age. Industrialization Not Automation. Compound Management. High Throughput Screening. Parallel Lead Optimization. Knowledge Management. ROI – How to Measure It? How to Get It?. Collaboration in a Virtual and Global Environment. From Genome to Drug: Ethical Issues.
| Erscheinungsdatum | 01.07.2021 |
|---|---|
| Reihe/Serie | Drug Discovery Series |
| Zusatzinfo | 39 Illustrations, black and white |
| Verlagsort | London |
| Sprache | englisch |
| Maße | 156 x 234 mm |
| Gewicht | 458 g |
| Themenwelt | Medizin / Pharmazie |
| Naturwissenschaften ► Biologie | |
| Technik | |
| ISBN-10 | 1-032-09994-1 / 1032099941 |
| ISBN-13 | 978-1-032-09994-1 / 9781032099941 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
was Mikroben, Tiere und Pflanzen eint und wie sie uns ernähren
Buch | Softcover (2024)
Lenos (Verlag)
CHF 31,95
was wir alle wissen sollten
Buch | Softcover (2023)
Mitteldeutscher Verlag
CHF 33,55
